Canada approves GSK's RSV vaccine for adults aged 50 to 59
Nov 5 (Reuters) -GSK GSK.L has received Canadian approval for its respiratory syncytial virus vaccine in adults between 50 and 59, the company said on Tuesday, making it the country's first authorized RSV shot for that age group.
The U.S. Centers for Disease Control and Prevention decided to hold off recommending the use of the vaccine, Arexvy, in adults under 60, despite the Food and Drug Administration approving it for that age group.
Arexvy is already approved in the United States and the European Union for use in adults between 50 and 59. It was previously approved only for those 60 and older in Canada, as is Pfizer's PFE.N RSV vaccine, Abrysvo.
RSV, which typically causes cold-like symptoms, is a leading cause of pneumonia in toddlers and older adults.
Hospitalizations associated with RSV in adults start to increase at the age of 50, GSK's interim Canada medical director, Michelle Horn, said.
Among Canadian adults 50 and older who are hospitalized with RSV, about 98% have at least one chronic condition, according to GSK.
The company has also filed regulatory submissions for the approval of Arexvy in adults aged 50 to 59 in Japan and other countries.
It expects to release data from two studies of the vaccine in adults 18 and above later in 2024.
Reporting by Puyaan Singh in Bengaluru; Editing by Pooja Desai
Related Assets
Latest News
Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.
All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.
Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.
